GLP1R and metabolic dysfunction-associated steatotic liver disease: Yu et al. [116] proposed that GLP-1 inhibits the activation of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome, and reduced the production of ROS by enhancing mitophagy in hepatocytes, eventually improving NAFLD and delaying the progression of NASH.